Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.Long-term adherence
International guidelines suggest long-term treatment with 5-ARI and α-blocker combination therapy.1–3
Patient counselling on the long-term effect of 5-ARIs on disease progression and risk of AUR/BPH-related surgery may be important to improve adherence.4
Continued treatment with 5-ARI therapy was associated with a reduced likelihood of AUR and BPH-related surgery5
In a retrospective analysis, for every additional 30 days that a patient remained on 5-ARI therapy, the likelihood of AUR and BPH-related surgery was reduced by 14% and 12%, respectively.*5
1-year AUR rates in patients discontinuing the therapy at specific intervals5
The figure has been independently created by GSK from the original data. The same results were first published in Gruschkus S, et al. P&T 2012;37(8):464–470
1-year BPH-related surgery rates in patients discontinuing the therapy at specific intervals5
The figure has been independently created by GSK from the original data. The same results were first published in Gruschkus S, et al. P&T 2012;37(8):464–470.
A retrospective analysis of US medical and pharmacy claims. N=17,739 for surgery analysis and N=17,293 for AUR analysis. Persistence with therapy was calculated from the index date to the last day covered by the last prescription before discontinuation of therapy, which was defined by a lapse of 30 days or more without medication. Examples of 5-ARI in this study include dutasteride and finasteride.5 *AUR: HR 0.860; 95% CI 0.852–0.867; BPH-related surgery: HR 0.884; 95% CI 0.867–0.902 (p<0.05 for both).5
Discussions with patients at risk of disease progression should include the benefits of long-term combination therapy to reduce this risk4
Video: The importance of long-term treatment with 5-ARI and alpha-blocker combination therapy
PM-RCH-DTT-VID-220042
Date of preparation: December 2022
Prescribing Information
Duodart Prescribing Information /API for Kuwait
Optional secondary information
Duodart Prescribing Information/API for UAE, Bahrain, Qatar and Oman
Optional secondary information
Abbreviations
5-ARI, 5-alpha reductase inhibitor; AUR, acute urinary retention; BPH, benign prostatic hyperplasia; CI, confidence interval; HR, hazard ratio; LUTS/BPH, lower urinary tract symptoms secondary to BPH.
References
- Gravas S, et al. EAU guidelines on the treatment of non-neurogenic male LUTS. 2022. Available at:
https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts. Accessed September 2022. - American Urological Association. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia. Published August 2021. Available at: https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline. Accessed September 2022.
- NICE. Lower urinary tract symptoms in men: management (CG97). Last updated 3 June 2015. Available at: https://www.nice.org.uk/guidance/cg97. Accessed September 2022.
- Cindolo L, et al. Eur Urol 2015;68(3):418–425.
- Gruschkus S, et al. P&T 2012;37(8):464–470.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via Gulf-KSA.Product-Complaints@gsk.com
Department of Pharmacovigilance & Drug Information |
دائرة التيقظ و المعلومات الدوائية المديرية العامة للصيدلة و الرقابة الدوائية وزارة الصحة, سلطنة عمان 0096822357687 / 0096822357686 :هاتف 0096822358489 :فاكس pharma-vigil@moh.gov.om :البريد الالكتروني www.moh.gov.om :الموقع الالكتروني |
Trademarks are owned by or licensed to the GSK group of companies.
©2022 GSK group of companies or its licensor. All rights reserved.
PM-RCH-DTT-WCNT-220004 Date of preparation: December 2022
